Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG

Phase 2 Not yet recruiting 12 enrolled Nationwide Children's Hospital

NaSingle-groupOpen-labelTreatment

Summary

The goal of this study is to further evaluate feasibility and tolerability of Opdualag for patients with replication repair deficient HGG, including DIPG.

Timeline

Start: 2027-03-01
Primary completion: 2033-03-01
Completion: 2038-03-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nivolumab	Monoclonal antibody	—	Intravenous
Subject	Relatlimab	Monoclonal antibody	—	Intravenous

Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG

Summary

Timeline

Drugs

Indications